Laurus Labs Ltd

Laurus Labs Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal code. The window will be shut from October 01, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ending September 30, 2026. This restriction applies to all designated persons, their immediate relatives, and connected persons. The date of the board meeting to approve these financial results will be communicated separately.

Laurus Labs Ltd has been assigned an Environmental, Social, and Governance (ESG) Score of 63 out of 100 for FY 2026 by NSE Sustainability Ratings and Analytics Limited. The company clarified that it did not engage NSE Sustainability for this score, and the report was independently prepared based on publicly available data. This independent assessment provides an external perspective on the company's ESG performance.

Laurus Labs Limited has received an order from the Hon'ble National Company Law Tribunal (NCLT), Amravati Special Branch, regarding its Composite Scheme of Arrangement. This scheme involves the demerger of Laurus Synthesis Private Limited (LSPL) into Sriam Labs Private Limited and the amalgamation of the remaining LSPL business undertakings with Laurus Labs. The NCLT has directed the petitioner companies to serve notices to concerned authorities and stakeholders. The next hearing date for the consideration of the Scheme is scheduled for September 10, 2026.

Laurus Labs reported a strong Q1 FY27 with a record revenue of ₹2,026 Crore, marking a 29% year-on-year increase. The company also saw significant growth in EBITDA, which rose by 66% to ₹644 Crore, with EBITDA margins expanding by 7.0% to 31.8%. Gross margins improved by over 3% to 62.7%. This performance was driven by strong commercial deliveries in the CDMO segment, particularly small molecules, and continued strength in the Affordable Medicines portfolio. The company also highlighted strategic advancements, including in-licensing two Antibody Drug Conjugates (ADCs) and securing new land parcels to support long-term growth.

Laurus Labs Ltd announced the retirement of Dr. Rajesh Koshy Chandy as an Independent Director, effective July 26, 2026. His retirement follows the completion of his second term as an Independent Director, which spanned from July 27, 2021, to July 26, 2026. The Board of Directors took note of this retirement during their meeting held on July 24, 2026. The board meeting commenced at 2:00 p.m. IST and concluded at 2:42 p.m. IST.

Laurus Labs Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results on July 24, 2026. The financial statements, along with the limited review reports from Deloitte Haskins & Sells LLP, are available on the company's website and stock exchange portals. The board meeting commenced at 2:00 PM IST and concluded at 2:42 PM IST.

Laurus Labs Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results on July 24, 2026. The company reported a total income of ₹2,035.49 crore and a net profit after tax of ₹361.99 crore for the quarter. The financial results, along with the limited review reports from Deloitte Haskins & Sells LLP, are available on the company's website and stock exchanges.

Laurus Labs Ltd has announced that its Board of Directors will convene on July 24, 2026. The primary agenda for this meeting is to consider and approve the un-audited financial results for the quarter ended June 30, 2026. Additionally, the company reiterated its trading window closure, which began on July 1, 2026, and will extend until July 26, 2026, for designated persons and their immediate relatives.

Laurus Labs Ltd has announced the conclusion of Mrs. Aruna Bhinge's tenure as an Independent Director, effective July 6, 2026. This marks the end of her second term with the company. The necessary disclosures related to this change, as per SEBI Master Circular, were previously submitted on April 30, 2026. This event signifies a change in the board composition.

Laurus Labs Ltd announced at its 21st Annual General Meeting held on July 2, 2026, the approval for the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors. Both appointments are for a term of five consecutive years, effective from July 2, 2026. The company confirmed that both individuals are not related to any existing Directors or Key Managerial Personnel and are not debarred from holding directorships by any regulatory authority. This move is in line with SEBI Listing Regulations.